866-997-4948(US-Canada Toll Free)

High-Grade Glioma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 69 Pages


Global Markets Directs, \'High-Grade Glioma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for High-Grade Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for High-Grade Glioma. High-Grade Glioma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for High-Grade Glioma.
  • A review of the High-Grade Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the High-Grade Glioma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
High-Grade Glioma Overview 7
Therapeutics Development 8
Pipeline Products for High-Grade Glioma - Overview 8
Pipeline Products for High-Grade Glioma - Comparative Analysis 9
High-Grade Glioma - Therapeutics under Development by Companies 10
High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes 12
High-Grade Glioma - Pipeline Products Glance 13
Clinical Stage Products 13
High-Grade Glioma - Products under Development by Companies 14
High-Grade Glioma - Products under Investigation by Universities/Institutes 15
High-Grade Glioma - Companies Involved in Therapeutics Development 16
Boehringer Ingelheim GmbH 16
Genentech, Inc. 17
Bayer AG 18
AngioChem Inc. 19
Stemline Therapeutics, Inc. 20
Tocagen Inc. 21
AROG Pharmaceuticals LLC 22
High-Grade Glioma - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Assessment by Therapeutic Class 35
Drug Profiles 37
nintedanib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ANG-1005 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Adenovirus-Thymidine Kinase Enzyme Gene Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Dendritic Cell Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
hydroxychloroquine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
sorafenib tosylate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SL-701 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
crenolanib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GDC-0084 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
High-Grade Glioma - Recent Pipeline Updates 55
High-Grade Glioma - Dormant Projects 65
High-Grade Glioma - Discontinued Products 66
High-Grade Glioma - Product Development Milestones 67
Featured News & Press Releases 67
Nov 22, 2013: Burzynski Clinic Presents the Results of Phase II Study of Antineoplastons in Children with Recurrent High-Grade Glioma at the Congress 67

Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Table


Number of Products under Development for High-Grade Glioma, H2 2013 8
Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H2 2013 16
High-Grade Glioma - Pipeline by Genentech, Inc., H2 2013 17
High-Grade Glioma - Pipeline by Bayer AG, H2 2013 18
High-Grade Glioma - Pipeline by AngioChem Inc., H2 2013 19
High-Grade Glioma - Pipeline by Stemline Therapeutics, Inc., H2 2013 20
High-Grade Glioma - Pipeline by Tocagen Inc., H2 2013 21
High-Grade Glioma - Pipeline by AROG Pharmaceuticals LLC, H2 2013 22
Assessment by Monotherapy Products, H2 2013 23
Assessment by Combination Products, H2 2013 24
Number of Products by Stage and Target, H2 2013 27
Number of Products by Stage and Mechanism of Action, H2 2013 30
Number of Products by Stage and Route of Administration, H2 2013 32
Number of Products by Stage and Molecule Type, H2 2013 34
Number of Products by Stage and Therapeutic Class, H2 2013 36
High-Grade Glioma Therapeutics - Recent Pipeline Updates, H2 2013 55
High-Grade Glioma - Dormant Projects, H2 2013 65
High-Grade Glioma - Discontinued Products, H2 2013 66

List of Chart


Number of Products under Development for High-Grade Glioma, H2 2013 8
Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 13
Assessment by Monotherapy Products, H2 2013 23
Number of Products by Top 10 Target, H2 2013 25
Number of Products by Stage and Top 10 Target, H2 2013 26
Number of Products by Top 10 Mechanism of Action, H2 2013 28
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 29
Number of Products by Top 10 Route of Administration, H2 2013 31
Number of Products by Stage and Top 10 Route of Administration, H2 2013 32
Number of Products by Top 10 Molecule Type, H2 2013 33
Number of Products by Stage and Top 10 Molecule Type, H2 2013 34
Number of Products by Top 10 Therapeutic Class, H2 2013 35
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *